SORT BY Relevancy
Throughout the GMO, biotech and agrochemical debates, we have witnessed the ultimate in corporate control and influence along with the disastrous impacts from the implementation of these technologies in our world food supply, pharmaceuticals, and the reckless tampering of DNA for profit-driven purposes. These impacts pose drastic effects to our human health and evolutionary process in a variety of ways. However, there is another critical aspect to the larger picture of which we are not talking enough about: the frightening consequences resulting from the biotech industry that now compromise the delicate balance of our planetary ecology and environment. As the hand of biotech continues to sweep across and outright ignore all reasonable boundaries of ethics and morality in its unquenchable thirst for power and profit, how close are we to the final curtain-call where nature, in its own inevitable wisdom, will protest against us and what cost will future generations have to pay for the mistakes made today?
At the May 2015 Chief Medical Officer's Summit in Boston, we featured a session on:
How Investors Assess R&D Biotech Management
Take a look at the details below:
In this session, we begin with a presentation on a perspective on the method of evaluating a disease space, which includes a comprehensive understanding of 1) the science, 2) the competitive landscape and 3) the management teams for each company. How does this get mapped out?
Following will be more discussion on:
Understanding the context of value proposition
Processes used to evaluate management and an understanding of competitive strategy
How best to convey your plans
How best to communicate with investors (before investment) and boards (afterwards) – via the CEO or directly?
Importance of clinical development plan expectations
Moderated by: Peter Kolchinsky, PhD Managing Director, RA Capital Management, LLC
Panelists: Jonathan Behr, PhD EIR and Market Sector Leader, Innovation, Partners Healthcare, David Berry, MD, PhD Partner, Flagship Ventures, Vikas Goyal, MBA Principal, SR One, and Jeffrey Moore, DPhil, MBA President, MPH Venture Management
The next CMO Summit is November 9-10 in Burlingame, California. It is one of the best face-to-face opportunities for R&D leaders in emerging biotechs to:
1. Address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits. 2. To create a network of CMOs & other R&D leaders from small to midsize life science companies to share ideas, solutions and support.
For information, visit www.theconferenceforum.org
Partial and full scholarships available for start-ups.
How do you know when changes in the market help you pivot to a better solution?
Ask Jamie Grooms. He is the CEO of the Florida Institute for the Commercialization of Public Research, a non-profit organization that assists new companies during their creation process. The institute leverages $2 billion of research funding to assist companies that will impact the global marketplace with scientific breakthroughs.
A major innovator in the biotech field, Jaime moved from a position of middle management at the Tissue Bank of the University of Florida, to become the CEO of Regeneration Technologies virtually overnight. That company, now known as RTI Biologics, is a global leader in implants from donor tissue.
“It’s not what you plan; it’s what you can see as an opportunity,” Jamie notes. His original plan was to use advanced bone implant technology in the sports medicine market, but sales weren’t matching expectations. So he re-examined his assumptions and pivoted into the spinal implant market, where his product was greeted enthusiastically on the basis of a strong pre-existing. This allowed him to make a greater impact on the market, which led to huge profits for Jamie and his team.
Success and expansion come with their own challenges. Jamie admits that at first he had trouble adapting to his sudden CEO status, (a position he defines as “the ultimate middle management service provider.”) He sought recommendations for an executive coach who taught to trust and develop his own brand of leadership. His ability to learn and adapt keeps Jamie at the frontline of the biotech field. What challenges are you facing as your brand expands?
A drop dead, massively big, upside opportunity exists for this pre-clinical stage biotech star. Motley Fool analyst Michael Douglass and contributor Todd Campbell discuss this and much more.
One of the latest practices in biotech is a process that allows DNA to be edited down to the letter. Known as CRISPR technology, scientists now have the ability to control gene mechanisms with unprecedented accuracy and without traditional invasive high-cost GMO procedures as they exist now. In effect, CRISPR is the evolution of GMO. All of this allows corporations to continue producing genetically altered foods without ever having to worry about legislation or labeling mandates. As consumer "right to know" demand increases and more companies are responding to protests by voluntarily labeling GMO products or removing them from their ingredients altogether, industry is well ahead of the game and consumers should not be fooled into complacency. CRISPR technology allows a crafty bypass because it is not recognized technically as a GMO process as is currently defined. Industry can use this technology to dodge existing regulations now, or in the future, and avoid GMO stigmas in public perception as they continue driving corporate profit. They would not have to disclose this new process to regulators or the public, rendering the hotly debated GMO labeling issue effectively moot. Present day loopholes in an obsolete agribusiness regulatory system may be the biggest challenge yet as consumers fight to stay informed and aware of what is happening to the manufacturing of food. Is CRISPR technology the ultimate bait and switch in the GMO debate?
Biotech stocks may have fallen sharply in the past few months, but that doesn't mean that everyone of them should be avoided. In this episode, we uncork some of our best ideas for investors to buy.
Exelixis has a newly approved melanoma drug hitting the market soon and Colorado voters will weigh in on universal healthcare in 2016.
Have you ever wanted to know what you’re really made of? Why your eyes are blue? Are you lactose intolerant? Are you a better sprinter or endurance athlete?
You don’t need to have a Ph-D or M-D to find out. The first home genetic test recently authorized to market by the F-D-A is here. And it can tell you about your health, traits and even your ancestry.
HERE NOW TO TALK ABOUT PERSONAL GENETICS IS DOCTOR EMILY DRABANT-CONLEY, Ph-D, VICE PRESIDENT OF 23-AND-ME.
1. WHY TAKE A GENETIC TEST? WHAT CAN YOU LEARN FROM YOUR D-N-A?
2. GENETICS SEEMS SO COMPLEX. HOW CAN THE AVERAGE PERSON UNDERSTAND OR USE THIS INFORMATION?
3. HOW DOES IT WORK AND HOW DO YOU PROTECT A CUSTOMER’S PRIVACY?
4. WHAT SHOULD PEOPLE DO WITH THIS INFORMATION IF THEY THINK THEY HAVE A MEDICAL CONDITION OR FAMILY HISTORY OF DISEASE?
5. WHAT KIND OF RESEARCH DO YOU DO? HOW DO PEOPLE PARTICIPATE
6. CAN THIS HELP SOMEONE FIND A RELATIVE IF THEY WERE ADOPTED?
Emily Drabant Conley, Ph.D. joined 23andMe in 2010. She is responsible for building strategic partnerships with pharmaceutical and biotech companies, forging research collaborations, and overseeing project execution across a range of therapeutic areas.
Join us for another awesome author chat with the one and only author, Joyce T Strand.
Joyce will be joining us to discuss her new book, "Landscape For Murder." Which was inspired by true events.
In the story Brynn Bancrofts winery is broken into. Plus the murder of a dear friend and of course the co-owner ex. With all that is going on can Brynn finally overcome her troubles and start to enjoy her life.
Author Joyce Strand is much like her character Jillian HIllcrest. Accept she didn't encounter murders. In her career served as the head of corporate communications at several biotech companies for more than 25 years. She currently lives in Southern CA where she is exploring the benefits of handcrafted wine from the Romano and San Diego area.
Tune in as well come author Joyce T Strand and her new book, "Landscape For Murder."
Stay tuned an keep it locked.
Jann Jaffe (Northwestern University, BA,MA) is an iPEC Certified Professional Coach, ELI-MP, and a COR.E Dynamics Specialist. Traumatic brain injuries cut short her successful career as an international opera/concert singer, and master class teacher, and drastically altered her life. Jann is dedicated to helping professional women achieve optimal success, realization of their potential, and passion, purpose, life balance and wellbeing in every aspect of their lives. Contact Jann at firstname.lastname@example.org
Sim Segal, president and founder of SimErgy Consulting, a firm specializing exclusively in enterprise risk management (ERM), is a globally-recognized ERM thought leader with 30 years of broad functional experience, deep technical knowledge, and ERM experience in a variety of sectors, such as insurance; banking; credit cards; technology; consumer goods; biotech; telecomm; hospitality; energy; services; timberland; education and research; non-profit organizations; and government agencies.
Segal is author of Corporate Value of Enterprise Risk Management (Wiley, March 2011), which is required reading on the syllabi of the Society of Actuaries (SOA) and leading universities in the U.S., Canada, the U.K., Australia, China, Italy, Croatia, and Egypt. He is also director of ERM programs at Columbia University. Segal is host of Risk Radio™, a weekly radio show featuring discussions and interviews on ERM topics. He has also conducted several ERM research studies. www.simergy.com